Abnormalities_NNS
of_IN
p16_NN
,_,
p15_NN
and_CC
CDK4_NN
genes_NNS
in_IN
recurrent_JJ
malignant_JJ
astrocytomas_NNS
._.

Abnormalities_NNS
in_IN
the_DT
p16_NN
,_,
p15_NN
and_CC
CDK4_NN
genes_NNS
that_WDT
regulate_VBP
transition_NN
through_IN
the_DT
G1_NN
phase_NN
of_IN
the_DT
cell_NN
cycle_NN
have_VBP
been_VBN
implicated_VBN
in_IN
the_DT
malignant_JJ
progression_NN
of_IN
astrocytomas_NNS
._.

The_DT
results_NNS
of_IN
the_DT
present_JJ
study_NN
demonstrate_VBP
that_IN
dysfunction_NN
of_IN
these_DT
genes_NNS
also_RB
occurs_VBZ
during_IN
recurrence_NN
of_IN
glial_JJ
tumors_NNS
that_WDT
were_VBD
highly_RB
malignant_JJ
at_IN
first_JJ
presentation_NN
._.

Analysis_NN
of_IN
10_CD
matched_VBN
pairs_NNS
of_IN
high_JJ
grade_NN
malignant_JJ
astrocytomas_NNS
and_CC
their_PRP$
subsequent_JJ
recurrences_NNS
identified_VBD
three_CD
distinct_JJ
groups_NNS
._.

The_DT
primary_JJ
and_CC
recurrent_JJ
tumors_NNS
in_IN
Group_NN
A_NN
did_VBD
not_RB
show_VB
structural_JJ
alterations_NNS
in_IN
the_DT
p16_NN
,_,
p15_NN
or_CC
CDK4_NN
genes_NNS
,_,
whereas_IN
homozygous_JJ
codeletion_NN
of_IN
p16_NN
and_CC
p15_NN
was_VBD
observed_VBN
in_IN
both_CC
primary_JJ
and_CC
recurrent_JJ
tumors_NNS
in_IN
Group_NN
B_NN
._.

The_DT
primary_JJ
tumors_NNS
in_IN
Group_NN
C_NN
had_VBD
a_DT
normal_JJ
profile_NN
of_IN
p16_NN
,_,
p15_NN
and_CC
CDK4_NN
at_IN
presentation_NN
._.

Upon_IN
recurrence_NN
,_,
however_RB
,_,
the_DT
tumors_NNS
sustained_VBD
either_CC
deletion_NN
of_IN
p16_NN
alone_RB
or_CC
codeletion_NN
of_IN
both_CC
p16_NN
and_CC
p15_NN
or_CC
amplification_NN
of_IN
CDK4_NN
._.

Analysis_NN
of_IN
the_DT
molecular_JJ
differences_NNS
between_IN
primary_JJ
anaplastic_JJ
astrocytomas\/glioblastomas_NNS
and_CC
their_PRP$
subsequent_JJ
recurrences_NNS
,_,
which_WDT
are_VBP
clinically_RB
indistinguishable_JJ
,_,
may_MD
provide_VB
better_JJR
therapeutic_JJ
options_NNS
for_IN
treatment_NN
._.

